HRP20210978T1 - Farmaceutski pripravak, postupci za liječenje i njegove uporabe - Google Patents
Farmaceutski pripravak, postupci za liječenje i njegove uporabe Download PDFInfo
- Publication number
- HRP20210978T1 HRP20210978T1 HRP20210978TT HRP20210978T HRP20210978T1 HR P20210978 T1 HRP20210978 T1 HR P20210978T1 HR P20210978T T HRP20210978T T HR P20210978TT HR P20210978 T HRP20210978 T HR P20210978T HR P20210978 T1 HRP20210978 T1 HR P20210978T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- process according
- patient
- equal
- individual
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 208000004611 Abdominal Obesity Diseases 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- YZGOOQZXQOPQNT-DNNBANOASA-N (2r,3r,4s,5s,6r)-2-[4-chloro-3-[[4-[(3s)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@]1(O)C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 YZGOOQZXQOPQNT-DNNBANOASA-N 0.000 claims 2
- 206010065941 Central obesity Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 208000036576 Obstructive uropathy Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000035487 diastolic blood pressure Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 201000002327 urinary tract obstruction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Farmaceutski pripravak, naznačen time, da sadrži SGLT2 inhibitor 1-kloro-4-(β-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran-3-iloksi)-benzil]-benzen za uporabu u postupku prevencije, usporavanja progresije, odgađanja ili liječenja renalne hiperfiltrativne ozljede kod pacijenta dijagnosticiranog s dijabetesom melitus tipa 1, kojemu je to potrebno.
2. Farmaceutski pripravak, naznačen time, da sadrži SGLT2 inhibitor 1-kloro-4-(β-D-glukopiranoz-1-il)-2-[4-((S)-tetrahidrofuran-3-iloksi)-benzil]-benzen za uporabu u postupku prevencije, usporavanja progresije, odgađanja ili liječenja renalne hiperfiltracije kod pacijenta dijagnosticiranog s dijabetesom melitus tipa 1.
3. Farmaceutski pripravak za uporabu u postupku prema patentnom zahtjevu 1 ili 2, naznačen time, da je pacijent pojedinac kojemu je dijagnosticirano ili pokazuje jedno ili više od sljedećih stanja:
(a) dijabetes melitus;
(b) prirođena ili stečena opstrukcijska uro/nefropatija;
(c) progresivna kronična bolest bubrega (prema engl. chronic kidney disease_CKD);
(d) akutno zatajenje bubrega (prema engl. acute renal failure_ARF);
(e) primatelji renalnih transplantata;
(f) davatelji renalnih transplantata; ili
(g) unilateralno totalno ili parcijalno nefrektomirani pacijenti.
4. Farmaceutski pripravak za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da pacijent ima GFR koji je jednak ili veći od 125 mL/min/1,73 m2.
5. Farmaceutski pripravak za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da pacijent ima GFR koji je jednak ili veći od 140 mL/min/1,73 m2.
6. Farmaceutski pripravak za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je pacijent:
(1) pojedinac s dijagnozom jednog ili više stanja koja se biraju iz skupine koju čine prekomjerna težina, pretilost, visceralna pretilost i abdominalna pretilost; ili
(2) pojedinac koji pokazuje jedno, dva ili više od sljedećih stanja:
(a) glukoza u krvi na tašte ili koncentracija glukoze u serumu iznosi više od 100 mg/dL, prvenstveno više od 125 mg/dL;
(b) glukoza u plazmi nakon jela jednaka je ili veća od 140 mg/dL;
(c) vrijednost HbA1c jednaka je ili veća od 6,0 %, jednaka ili veća od 6,5%, ili jednaka ili veća od 8,0 %; ili
(3) pojedinac kod kojega su prisutna jedno, dva, tri ili više od sljedećih stanja:
(a) pretilost, visceralna pretilost i/ili abdominalna pretilost,
(b) razina triglicerida u krvi ≥ 150 mg/dL,
(c) razina HDL-kolesterola u krvi < 40 mg/dL kod ženskih pacijenata i < 50 mg/dL kod muških pacijenata,
(d) sistolički krvni tlak ≥ 130 mm Hg i dijastolički krvni tlak ≥ 85 mm Hg,
(e) razina glukoze u krvi na tašte ≥ 100 mg/dL; ili
(4) pojedinac koji ima morbidnu pretilost.
7. Farmaceutski pripravak za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da farmaceutski pripravak dodatno sadrži jedan ili više farmaceutski prihvatljivih nosača.
8. Farmaceutski pripravak za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da farmaceutski pripravak sadrži inhibitor SGLT-2 u rasponu od 1 mg do 25 mg.
9. Farmaceutski pripravak za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da farmaceutski pripravak sadrži 1 mg, 2,5 mg, 5 mg, 7,5 mg, 10 mg, 12,5 mg, 15 mg, 20 mg ili 25 mg inhibitora SGLT-2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505598P | 2011-07-08 | 2011-07-08 | |
| EP12730993.8A EP2729151B1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
| PCT/EP2012/062922 WO2013007557A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210978T1 true HRP20210978T1 (hr) | 2021-09-17 |
Family
ID=46420221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210978TT HRP20210978T1 (hr) | 2011-07-08 | 2021-06-19 | Farmaceutski pripravak, postupci za liječenje i njegove uporabe |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US20130035298A1 (hr) |
| EP (2) | EP2729151B1 (hr) |
| JP (2) | JP2014520778A (hr) |
| KR (1) | KR20140041697A (hr) |
| CN (2) | CN103732230A (hr) |
| AR (1) | AR087729A1 (hr) |
| AU (1) | AU2012283229B2 (hr) |
| BR (1) | BR112014000380A2 (hr) |
| CA (1) | CA2837787C (hr) |
| CY (1) | CY1124307T1 (hr) |
| DK (1) | DK2729151T3 (hr) |
| EA (1) | EA025497B1 (hr) |
| ES (1) | ES2871904T3 (hr) |
| HR (1) | HRP20210978T1 (hr) |
| HU (1) | HUE054621T2 (hr) |
| LT (1) | LT2729151T (hr) |
| MX (1) | MX2014000010A (hr) |
| PL (1) | PL2729151T3 (hr) |
| PT (1) | PT2729151T (hr) |
| RS (1) | RS61827B1 (hr) |
| SI (1) | SI2729151T1 (hr) |
| WO (1) | WO2013007557A1 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| CN102574829B (zh) | 2009-09-30 | 2015-07-01 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苄基-苯衍生物的制备方法 |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HRP20220365T1 (hr) * | 2013-04-18 | 2022-05-13 | Boehringer Ingelheim International Gmbh | Farmaceutski pripravak, postupci za liječenje i njegove uporabe |
| US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
| WO2015110402A1 (en) * | 2014-01-23 | 2015-07-30 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| JP6571100B2 (ja) | 2014-03-04 | 2019-09-04 | 大塚製薬株式会社 | イオヘキソール粉末及びそれを使用する方法 |
| WO2016051368A1 (en) * | 2014-10-01 | 2016-04-07 | Mylan Laboratories Ltd | Complex of amorphous empagliflozin and a cyclodextrin |
| CN107223052A (zh) * | 2015-03-27 | 2017-09-29 | 豪夫迈·罗氏有限公司 | 包含sembragiline的药物制剂 |
| MA43709A (fr) * | 2016-03-16 | 2018-11-28 | Boehringer Ingelheim Int | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations |
| MA46742A (fr) * | 2016-11-10 | 2019-09-18 | Boehringer Ingelheim Int | Composition pharmaceutique, méthodes de traitement et leurs utilisations |
| WO2020089760A1 (en) * | 2018-11-01 | 2020-05-07 | Glenmark Pharmaceuticals Limited | Fixed dose pharmaceutical composition comprising combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof |
| US11655240B1 (en) * | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| SI1730131T1 (sl) | 2004-03-16 | 2012-08-31 | Boehringer Ingelheim Int | Glukopiranozil-substituirani benzenski derivati, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| JP2008524162A (ja) | 2004-12-16 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法 |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DK1881850T3 (da) | 2005-05-13 | 2011-01-03 | Lilly Co Eli | GLP-1-PEGylerede forbindelser |
| EP1924571B1 (en) | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200745075A (en) | 2005-09-08 | 2007-12-16 | Boehringer Ingelheim Int | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| JP2009531291A (ja) | 2006-02-15 | 2009-09-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法 |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| CA2656847A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| WO2008049923A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| EP2081569A2 (en) | 2006-11-09 | 2009-07-29 | Boehringer Ingelheim International GmbH | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| WO2009020802A2 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| CA2751833C (en) * | 2009-02-13 | 2018-11-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| CN102549005B (zh) | 2009-09-30 | 2015-08-26 | 贝林格尔.英格海姆国际有限公司 | 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-[4-((S)-四氢呋喃-3-基氧基)-苄基]-苯的晶型的制备方法 |
| CN102574829B (zh) | 2009-09-30 | 2015-07-01 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苄基-苯衍生物的制备方法 |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
-
2012
- 2012-07-02 US US13/539,713 patent/US20130035298A1/en not_active Abandoned
- 2012-07-03 BR BR112014000380A patent/BR112014000380A2/pt not_active IP Right Cessation
- 2012-07-03 WO PCT/EP2012/062922 patent/WO2013007557A1/en active Application Filing
- 2012-07-03 SI SI201231915T patent/SI2729151T1/sl unknown
- 2012-07-03 MX MX2014000010A patent/MX2014000010A/es active IP Right Grant
- 2012-07-03 HU HUE12730993A patent/HUE054621T2/hu unknown
- 2012-07-03 ES ES12730993T patent/ES2871904T3/es active Active
- 2012-07-03 RS RS20210582A patent/RS61827B1/sr unknown
- 2012-07-03 JP JP2014517770A patent/JP2014520778A/ja active Pending
- 2012-07-03 CA CA2837787A patent/CA2837787C/en active Active
- 2012-07-03 EA EA201400119A patent/EA025497B1/ru not_active IP Right Cessation
- 2012-07-03 PT PT127309938T patent/PT2729151T/pt unknown
- 2012-07-03 AU AU2012283229A patent/AU2012283229B2/en active Active
- 2012-07-03 KR KR1020147000445A patent/KR20140041697A/ko not_active Application Discontinuation
- 2012-07-03 EP EP12730993.8A patent/EP2729151B1/en not_active Revoked
- 2012-07-03 CN CN201280038791.6A patent/CN103732230A/zh active Pending
- 2012-07-03 DK DK12730993.8T patent/DK2729151T3/da active
- 2012-07-03 EP EP21157166.6A patent/EP3854404A1/en active Pending
- 2012-07-03 CN CN201611176372.5A patent/CN106692126A/zh active Pending
- 2012-07-03 LT LTEP12730993.8T patent/LT2729151T/lt unknown
- 2012-07-03 PL PL12730993T patent/PL2729151T3/pl unknown
- 2012-07-06 AR ARP120102475A patent/AR087729A1/es unknown
-
2016
- 2016-01-07 JP JP2016001599A patent/JP2016121156A/ja active Pending
-
2018
- 2018-03-27 US US15/936,927 patent/US20180214468A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,324 patent/US20200268777A1/en not_active Abandoned
-
2021
- 2021-06-14 CY CY20211100523T patent/CY1124307T1/el unknown
- 2021-06-14 US US17/346,475 patent/US20220096505A1/en not_active Abandoned
- 2021-06-19 HR HRP20210978TT patent/HRP20210978T1/hr unknown
-
2023
- 2023-09-06 US US18/461,850 patent/US20230405032A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR087729A1 (es) | 2014-04-16 |
| US20180214468A1 (en) | 2018-08-02 |
| EP2729151A1 (en) | 2014-05-14 |
| AU2012283229A1 (en) | 2014-01-09 |
| CA2837787C (en) | 2021-09-14 |
| SI2729151T1 (sl) | 2021-06-30 |
| CA2837787A1 (en) | 2013-01-17 |
| EA025497B1 (ru) | 2016-12-30 |
| NZ618546A (en) | 2016-02-26 |
| JP2014520778A (ja) | 2014-08-25 |
| EP3854404A1 (en) | 2021-07-28 |
| CN106692126A (zh) | 2017-05-24 |
| RS61827B1 (sr) | 2021-06-30 |
| HUE054621T2 (hu) | 2021-09-28 |
| US20200268777A1 (en) | 2020-08-27 |
| CY1124307T1 (el) | 2022-07-22 |
| US20220096505A1 (en) | 2022-03-31 |
| PT2729151T (pt) | 2021-05-25 |
| US20130035298A1 (en) | 2013-02-07 |
| JP2016121156A (ja) | 2016-07-07 |
| US20230405032A1 (en) | 2023-12-21 |
| DK2729151T3 (da) | 2021-06-28 |
| ES2871904T3 (es) | 2021-11-02 |
| EA201400119A1 (ru) | 2014-08-29 |
| KR20140041697A (ko) | 2014-04-04 |
| WO2013007557A1 (en) | 2013-01-17 |
| CN103732230A (zh) | 2014-04-16 |
| AU2012283229B2 (en) | 2017-06-15 |
| PL2729151T3 (pl) | 2021-10-18 |
| LT2729151T (lt) | 2021-05-25 |
| MX2014000010A (es) | 2014-02-27 |
| BR112014000380A2 (pt) | 2017-02-14 |
| EP2729151B1 (en) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210978T1 (hr) | Farmaceutski pripravak, postupci za liječenje i njegove uporabe | |
| Levy et al. | Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)? | |
| Kim et al. | Inhibition of influenza virus replication by plant-derived isoquercetin | |
| Slater et al. | Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review | |
| Luo et al. | Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy | |
| HRP20170022T1 (hr) | Farmaceutski sastav koji obuhvaća derivat benzena supstituiran glukopiranozilom | |
| Shi et al. | Nuciferine improves high-fat diet-induced obesity via reducing intestinal permeability by increasing autophagy and remodeling the gut microbiota | |
| JP4997241B2 (ja) | 慢性炎症性腸疾患の患者における鉄欠乏状態の経口処置用の薬剤を調製するための鉄（ｉｉｉ）複合化合物 | |
| Riaz et al. | Outbreak of dengue fever in Karachi 2006: a clinical perspective | |
| JP2016510795A5 (hr) | ||
| HRP20221368T1 (hr) | Terapijske uporabe empagliflozina | |
| JP2017504649A5 (hr) | ||
| WO2010023422A8 (en) | Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation | |
| Dentali et al. | Efficacy and safety of extended thromboprophylaxis for medically ill patients | |
| JP2018527374A5 (hr) | ||
| Eguchi et al. | Branched-chain amino acids protect the liver from cirrhotic injury via suppression of activation of lipopolysaccharide-binding protein, toll-like receptor 4, and signal transducer and activator of transcription 3, as well as Enterococcus faecalis translocation | |
| Rafieian-Kopaei et al. | Soy protein and chronic kidney disease: An updated review | |
| Mao et al. | Ghrelin protects against palmitic acid or lipopolysaccharide-induced hepatocyte apoptosis through inhibition of MAPKs/iNOS and restoration of Akt/eNOS pathways | |
| Szuster-Ciesielska et al. | Betulin, betulinic acid and butein are inhibitors of acetaldehyde-induced activation of liver stellate cells | |
| Mascaraque et al. | The small intestinal mucosa acts as a rutin reservoir to extend flavonoid anti-inflammatory activity in experimental ileitis and colitis | |
| Heung et al. | Entanglement of sepsis, chronic kidney disease, and other comorbidities in patients who develop acute kidney injury | |
| Tanriover et al. | On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease | |
| Sachs et al. | Medical implications of hyperuricemia | |
| Timper et al. | Diabetes mellitus Type 2–the new face of an old lady | |
| Almazmomi et al. | Acute kidney injury: Definition, management, and promising therapeutic target |